Ramesh Jayaraman

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

Stefan Hart, K C Goh, Veronica Novotny‐Diermayr et al. · Leukemia · 2011 · 199 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma

Anthony D. William, Angeline C.-H. Lee, Stéphanie Blanchard et al. · Journal of Medicinal Chemistry · 2011 · 198 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

Anas Younes, Jorge Romaguera, Michelle A. Fanale et al. · Journal of Clinical Oncology · 2012 · 139 citations

Medicine, Oncology, Pharmacology +13

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

K C Goh, Veronica Novotny‐Diermayr, Stefan Hart et al. · Leukemia · 2011 · 129 citations

Medicine, Medicinal Chemistry, Oncology +11

Discovery of Kinase Spectrum Selective Macrocycle (16<i>E</i>)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer

Anthony D. William, Angeline C.-H. Lee, Kee Chuan Goh et al. · Journal of Medicinal Chemistry · 2011 · 100 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16